

In the claims:

Please amend the following claims as indicated.

1-27. (Cancelled)

28. (Currently amended) A method for inducing an immune response ~~a host to produce Ab3 antibodies that specifically bind to prostate specific antigen~~ comprising administering to the ~~host an Ab1~~ a mammal an antibody or antigen-binding fragment thereof that specifically binds to an epitope of circulating prostate specific antigen, said epitope being an epitope to which ~~wherein the epitope is specifically bound by a monoclonal antibody produced by a hybridoma that has ATCC Designation Number HB-12526~~ specifically binds.

29. (Cancelled)

30. (Currently amended) The method of claim ¹28, wherein the ~~Ab1~~ antibody is a monoclonal antibody ~~produced by a hybridoma that has ATCC Designation Number HB-12526~~.

31. (Cancelled)

³32. (Currently amended) The method of claim ¹28, wherein the ~~Ab1~~ antibody or antigen-binding fragment thereof is conjugated to an immunogenic carrier.

⁴33. (Previously presented) The method of claim ³32, wherein the immunogenic carrier is keyhole limpet hemocyanin.

34-35. (Cancelled)

36. (Currently amended) The method of claim 28, wherein the ~~Ab1~~ antibody is selected from the group consisting of ~~one member of an immunologic pair; an antibody; a monoclonal antibody, [[;]] an antibody fragment thereof; a single chain antibody[[;]], a humanized antibody, or fragment thereof; and a chimeric antibody or fragment thereof.~~

⁶
~~37~~. (Currently amended) The method according to claim ~~17~~ or ~~28~~¹, wherein the ~~Ab1~~
antibody or antigen binding fragment thereof is a xenogenic antibody or antigen-binding
fragment thereof.

⁷
~~38~~. (Currently amended) The method according to claim ~~17~~ or ~~28~~¹, wherein the ~~Ab1~~
antibody or antigen-binding fragment thereof is formulated with an adjuvant.

39. (Cancelled)

⁸
~~40~~. (Currently amended) The method of claim ~~39~~ ~~28~~¹, wherein the ~~low dose~~antibody or
antigen-binding fragment thereof is formulated at a dose of from about 0.1 µg to about 2 mg per
kilogram of body weight of the ~~patient~~mammal.

⁹
~~41~~. (Currently amended) The method of claim ~~39~~ ~~28~~¹, wherein the ~~low dose~~antibody or
antigen-binding fragment thereof is formulated at a dose of from about 1.0 µg to about 200 µg
per kilogram of body weight of the ~~patient~~mammal.